UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) | Delaware | 001-39318 | 46-3973463 | | --- | --- | --- | | (State or Other Jurisdiction | (Commission | (IRS Employer ...

Exhibit 99.1 Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights Monday, March 18, 2024 DALLAS—(Business Wire)—Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning ("ML") platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the fourth quarter and fiscal year ended Dec ...

Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Panna Sharma - President and Chief Executive Officer David Margrave - Chief Financial Officer Conference Call Participants Operator Good afternoon, and welcome to our Third Quarter 2023 Earnings Call. As a reminder, this call is being recorded and all attendees are in a listen-only mode. We will open the call for questions and answers after our management’s presentation. A webcast replay of to ...

November 8th, 2023 4:30 PM Eastern Time r m a 1 > Lantern P h a r m a | --- | --- | --- | --- | --- | --- | |--------------------------|-------|--------------------------------|-------|----------------|-------| | | | | | | | | Contents | | Speakers | | | | | 01 Introduction | | Panna Sharma CEO and President | CFO | David Margrave | | | 02 Q3 2023 Highlights | | | | | | | 03 Financial Highlights | | | | | | | 04 Q&A | | | | | | (*Parker et al., 2021) RADR® can predict and stratify real-world patients for cl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. Washington, D.C. 20549 (Exact name of registrant as specified in its charter) | Delaware | 001-39318 | 46-3973463 | | --- | --- | --- | | (State or Other Jurisdiction | (Commission | (IRS ...

Lantern Pharma Inc. (NASDAQ:LTRN) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Nicole Leber – Investor Relations Panna Sharma – Chief Executive Officer David Margave – Chief Financial Officer Conference Call Participants Nicole Leber Good afternoon, everyone. I’m Nicole Leber with Investor Relations here at Lantern Pharma. Welcome to our Second Quarter 2023 Earnings Call. I will be your host for today’s call. As a reminder, this call is being recorded and all attendees are ...

Second Quarter 2023 Operating & Financial Results Conference Call / Webinar NASDAQ: LTRN 1 Nasdaq: LTRN RADR® can predict and stratify real-world patients for clinical trials with 88% Accuracy LANTERN'S DRUG DEVELOPMENT MODEL AND OBJECTIVES Accelerated timelines; reduced costs and risks Lantern's diverse & unique AI-driven pipeline of 14 drug programs includes the Phase 2 Harmonic™ trial and RADR® collaborations August 9th, 2023 4:30 PM Eastern Time Forward Looking Statements > Lantern P h a r m a Lantern i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number) ...

Lantern Pharma Inc. (NASDAQ:LTRN) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Nicole Leber - Investor Relations Associate Panna Sharma - Chief Executive Officer and President David Margrave - Chief Financial Officer and Secretary Conference Call Participants Michael King - EF Hutton Nicole Leber Good afternoon, everyone. I'm Nicole Weber with Investor Relations here at Lantern Pharma. Welcome to our First Quarter 2023 Earnings Call. I will be your host for today's call. As a ...

NASDAQ: LTRN LP-300 has additional MoA's that can give it chemo-protective and chemo-sensitization properties • Reduce glutathione/thioredoxin mediated tumor resistance to therapy • Nephrotoxicity protection against chemotherapy LP-300 binding to ALK inactivates it in a dose dependent manner LP-184 has Blockbuster Potential Across Multiple Cancers as a Single Agent or in Combination Therapy DDR Deficient Tumors Including: Phase 1 trial in 2023* *Anticipated Timeline • Low nanomolar anti-cancer potency, heal ...